ACTRN12620000891921已完成1 期
A phase I, open label, two-way crossover study to determine the pharmacokinetic effects, safety, and tolerability of single doses of sublingual cannabidiol wafers vs. cannabidiol oil in healthy volunteers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Healthy volunteer with no major medical conditions and a BMI between 19.0 to 25.0 kg/m2 inclusive. Females must be using acceptable birth control and not planning to become pregnant.
排除标准
- •Must not have used cannabinoid based medicine in the last 6 months. No blood donation within the past month. Must not consume grapefruit juice within 48 hours of study visits.
研究者
相似试验
进行中（未招募）
不适用
A study in healthy subjects to determine how the levels of drug in the blood vary following administration ofsingle oral capsule doses of 20 mg lomitapide on two separate occasionsHealthy volunteersMedDRA version: 16.0Level: LLTClassification code 10024055Term: LDL cholesterol increasedSystem Organ Class: 100000004848EUCTR2013-002692-17-GBAegerion Pharmaceuticals Inc
尚未招募
不适用
A Phase I, open-label, randomized, 2-way crossover trial in 40 healthy subjects to investigate the potential pharmacokinetic interactions between telaprevir and darunavir/ritonavir and between telaprevir and fosamprenavir/ritonavir at steady-statehepatitis C / liver disease10047438NL-OMON32330TIBOTEC PHARMACEUTICALS In Nederland vertegenwoordigd door Janssen-Cilag B.V. afdeling GCO40
尚未招募
不适用
A Phase I, open-label, randomized, 2-way crossover trial in 2 parallel panels of 20 healthy subjects each to investigate the pharmacokinetic interaction between lopinavir/ritonavir (LPV/rtv) and telaprevir, and between atazanavir/ritonavir (ATV/rtv) and telaprevir, all at steady-state.NL-OMON30839Tibotec Pharmaceuticals40
暂停
1 期
To evaluate Safety and Pharmacokinetics of Briogyn (Follitropin alfa, Cadila HealthCare)CTRI/2020/12/029469PSK Pharma LLC
已完成
不适用
A phase 1, open-label, randomized, 2-way crossover study to assess the effects of acid reducing agent(s) on the pharmacokinetics of a single oral dose of JNJ-64417184 in healthy adult participantsNL-OMON50152Janssen-Cilag International NV14